In a prospective study of 138 patients who received anti-PD-1 monotherapy [4], all eight patients with grade 3 or worse ICI-ILD (including three patients with grade 5 ILD) developed ICI-ILD within 60 days of initiating the ICI monotherapy. The gene discussed is PDCD1; the disease is interstitial lung disease.